Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
← catalyst calendarNCT02227251 · readout ≤ 134 d
Sponsored by Karyopharm Therapeutics Inc (industry) · KPTI — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
244estimated
Sites
175
Countries
Australia, Austria, Belgium +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Nov 2014 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2014-08-28 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diffuse Large B-cell Lymphoma
Interventions
- Drug: Selinexor — also filed as KPT-330
- Drug: Selinexor — also filed as KPT-330
- Drug: Selinexor — also filed as KPT-330
Primary outcomes
what the primary-completion date above is the date OFPart 1: Overall Response Rate (ORR)
measured One year
Part 2: Overall Response Rate (ORR) Based on Lugano Criteria
measured From initial randomization until date of disease progression or death (maximum of 1 year from Part 2 randomization)
Publications
- PMID 35078739 — linked by the registry
- PMID 34271963 — linked by the registry
- PMID 33528286 — linked by the registry
- PMID 32589977 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · KPTI's whole pipeline · Catalyst calendar · Every registered study · What changed